Samsara BioCapital, LLC recently filed their 13F report for the second quarter of 2022, which ended on 2022-06-30.
The 13F report details which stocks were in a guru’s equity portfolio at the end of the quarter, though investors should note that these filings are limited in scope, containing only a snapshot of long positions in U.S.-listed stocks and American depository receipts as of the quarter’s end. They are not required to include international holdings, short positions or other types of investments. Still, even this limited filing can provide valuable information.
628 Middlefield Road Palo Alto, CA 94301
As of the latest 13F report, the guru’s equity portfolio contained 57 stocks valued at a total of $375.00Mil. The top holdings were KDNY(24.07%), NKTX(9.42%), and SRRK(6.73%).
According to GuruFocus data, these were Samsara BioCapital, LLC’s top five trades of the quarter.
Scholar Rock Holding Corp
During the quarter, Samsara BioCapital, LLC bought 4,259,217 shares of NAS:SRRK for a total holding of 4,598,828. The trade had a 6.23% impact on the equity portfolio. During the quarter, the stock traded for an average price of $7.27.
On 08/16/2022, Scholar Rock Holding Corp traded for a price of $11.29 per share and a market cap of $583.02Mil. The stock has returned -71.21% over the past year.
GuruFocus gives the company a financial strength rating of 5 out of 10 and a profitability rating of 1 out of 10.
In terms of valuation, Scholar Rock Holding Corp has a price-book ratio of 1.77, a EV-to-Ebitda ratio of -2.39 and a price-sales ratio of 9.86.
The price-to-GF Value ratio is 0.36, earning the stock a GF Value rank of 2.
Nkarta Inc
During the quarter, Samsara BioCapital, LLC bought 833,333 shares of NAS:NKTX for a total holding of 2,868,035. The trade had a 2.74% impact on the equity portfolio. During the quarter, the stock traded for an average price of $13.1.
On 08/16/2022, Nkarta Inc traded for a price of $18.39 per share and a market cap of $894.80Mil. The stock has returned -51.14% over the past year.
GuruFocus gives the company a financial strength rating of 7 out of 10. There is insufficient data to calculate the stock’s profitability rating.
In terms of valuation, Nkarta Inc has a price-book ratio of 2.67 and a EV-to-Ebitda ratio of -8.23.
Lyra Therapeutics Inc
The guru established a new position worth 1,777,251 shares in NAS:LYRA, giving the stock a 2.68% weight in the equity portfolio. Shares traded for an average price of $5.42 during the quarter.
On 08/16/2022, Lyra Therapeutics Inc traded for a price of $6.28 per share and a market cap of $199.87Mil. The stock has returned -9.51% over the past year.
GuruFocus gives the company a financial strength rating of 8 out of 10 and a profitability rating of 1 out of 10.
In terms of valuation, Lyra Therapeutics Inc has a price-book ratio of 1.78, a EV-to-Ebitda ratio of -1.78 and a price-sales ratio of 14.06.
Chinook Therapeutics Inc
During the quarter, Samsara BioCapital, LLC bought 570,000 shares of NAS:KDNY for a total holding of 5,161,888. The trade had a 2.66% impact on the equity portfolio. During the quarter, the stock traded for an average price of $15.71.
On 08/16/2022, Chinook Therapeutics Inc traded for a price of $21.01 per share and a market cap of $1.32Bil. The stock has returned 68.08% over the past year.
GuruFocus gives the company a financial strength rating of 6 out of 10. There is insufficient data to calculate the stock’s profitability rating.
In terms of valuation, Chinook Therapeutics Inc has a price-book ratio of 2.61, a EV-to-Ebitda ratio of -12.75 and a price-sales ratio of 20.14.
HilleVax Inc
The guru established a new position worth 762,577 shares in NAS:HLVX, giving the stock a 2.22% weight in the equity portfolio. Shares traded for an average price of $11.87 during the quarter.
On 08/16/2022, HilleVax Inc traded for a price of $12.35 per share and a market cap of $412.83Mil. The stock has returned 0.00% over the past year.
GuruFocus gives the company a financial strength rating of 5 out of 10 and a profitability rating of 2 out of 10.
In terms of valuation, HilleVax Inc has a EV-to-Ebitda ratio of -4.78.
Please note, the numbers and facts quoted are as of the writing of this article and may not factor in the latest trading data or company announcements.
Want to provide feedback on this article? Have questions or concerns? Get in touch with us here, or email us at [email protected]!
This article is general in nature and does not represent the opinions of GuruFocus or any of its affiliates. This article is not intended to be financial advice, nor does it constitute investment advice or recommendations. It was written without regard to your individual situation or financial goals. We aim to bring you fundamental, data-driven analysis, The information on this site is in no way guaranteed for completeness, accuracy or in any other way.
